These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35937823)

  • 1. Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.
    Cai Y; Liu Z; Jiang L; Ma D; Zhou Z; Ju H; Zhu Y
    Front Endocrinol (Lausanne); 2022; 13():871830. PubMed ID: 35937823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Lymph Node Metastasis in Patients With T1/T2 Gastroduodenal Neuroendocrine Neoplasms: Implications for Endoscopic Treatment.
    Zhou YJ; Wang QW; Zhang QW; Chen JN; Wang XY; Gao YJ; Li XB
    Front Endocrinol (Lausanne); 2021; 12():658392. PubMed ID: 34122337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functional Gastroenteropancreatic Neuroendocrine Tumors.
    Shannon AB; Straker RJ; Fraker DL; Miura JT; Karakousis GC
    J Am Coll Surg; 2022 May; 234(5):900-909. PubMed ID: 35426404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors of Small Non-Functional Pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study.
    Tan Q; Wang X; Li Y; Liu Y; Liu X; Ke N
    Front Endocrinol (Lausanne); 2022; 13():907415. PubMed ID: 35873006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroenteropancreatic neuroendocrine tumors: Role of surgery.
    Sauvanet A
    Ann Endocrinol (Paris); 2019 Jun; 80(3):175-181. PubMed ID: 31079831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.
    Martin JA; Warner RRP; Aronson A; Wisnivesky JP; Kim MK
    Pancreas; 2017 Oct; 46(9):1214-1218. PubMed ID: 28902794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.
    Chiramel J; Almond R; Slagter A; Khan A; Wang X; Lim KHJ; Frizziero M; Chakrabarty B; Minicozzi A; Lamarca A; Mansoor W; Hubner RA; Valle JW; McNamara MG
    World J Clin Oncol; 2020 Apr; 11(4):205-216. PubMed ID: 32355642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
    Noor M; Huber AR; Cates JMM; Gonzalez RS
    Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis.
    Zhang XF; Xue F; Dong DH; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Lv Y; Maithel SK; Pawlik TM
    Ann Surg; 2021 Jul; 274(1):e28-e35. PubMed ID: 31356277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is endoscopic resection appropriate for type 3 gastric neuroendocrine tumors? Retrospective multicenter study.
    Hirasawa T; Yamamoto N; Sano T
    Dig Endosc; 2021 Mar; 33(3):408-417. PubMed ID: 32578248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
    Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?
    DePalo DK; Lee RM; Lopez-Aguiar AG; Gamboa AC; Rocha F; Poultsides G; Dillhoff M; Fields RC; Idrees K; Nathan H; Abbott D; Maithel SK; Russell MC;
    J Surg Oncol; 2019 Nov; 120(6):919-925. PubMed ID: 31385621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.